Chronic Pain News and Research

RSS

Patient society representatives gather to discuss new strategies to fight osteoporosis

Today, more than 130 osteoporosis patient society representatives gathered in Valencia, Spain for the opening of the 13th IOF World Wide Conference of Osteoporosis Patient Societies.

19 Mar 2011

Non-adherence to chronic opioid therapy increases healthcare costs and hospital days

Patients undergoing opioid therapy for chronic pain who may not be following their prescription regimen have significantly higher overall healthcare costs, Ameritox Ltd. announced recently. The study was published in The American Journal of Managed Care.

18 Mar 2011

Electric devices can improve aging skin

It may seem as if new developments to combat aging skin are being introduced faster than the speed of light. At the forefront of the research, dermatologists are underpinning these advancements, refining the basic understanding of how the skin ages in order to develop more effective non-invasive cosmetic procedures and products.

16 Mar 2011

AstraZeneca commences NKTR-118 Phase III clinical programme for opioid-induced constipation

AstraZeneca today announced enrolment of the first patient in the Phase III clinical programme for NKTR-118, an oral peripherally-acting opioid antagonist being investigated for the treatment of opioid-induced constipation (OIC).

16 Mar 2011

Research links frequent prescribing to opioid-related deaths

Some physicians are prescribing opioids such as OxyContin 55 times as often as others, according to a new study led by St. Michael's Hospital and the Institute for Clinical Evaluative Sciences (ICES). The study found most opioid-related deaths occur among patients treated by physicians who frequently prescribe opioids, suggesting doctors who prescribe a lot of opioids may not be doing so safely.

15 Mar 2011

St. Joseph's Hospital launches new neuromodulation center in Barrow

St. Joseph's Hospital and Medical Center's Barrow Neurological Institute has received a $10.1 million donation, the largest single gift in the organization's history and one of the biggest ever given to any Arizona hospital.

10 Mar 2011

FDA clears Tenex Health's TX1 Tissue Removal System

Tenex Health today announces FDA 510(k) clearance of the TX1 Tissue Removal System. This portable, self-contained system offers precise soft tissue removal for tendons and other soft tissues with intended use in the elbow, knee, ankle, foot, and shoulder.

9 Mar 2011

'Cross-talk' between two major biological pathways may hold a clue for chronic pain treatment

Researchers at the University of California, Davis have discovered a "cross-talk" between two major biological pathways that involve pain-research that may pave the way to new approaches to understanding and controlling chronic pain.

9 Mar 2011

State News: N.Y. Medicaid's compromise; Va. ups health spending; Medi-Cal ruling

One of the most familiar criticisms of the new national health care law is that it doesn't do much to contain costs. ... Cost controls are supposed to come later. "Later" has arrived now for Massachusetts' statewide plan, enacted in 2006 and similar in many ways to the federal one. Some 98 percent of all adults and nearly 100 percent of all children are covered, but costs have spiraled out of control.

28 Feb 2011

AHRQ: $52.2 billion spent on prescription drugs for treatment of metabolic conditions during 2008

Insurers and consumers spent $52.2 billion on prescription drugs in 2008 for outpatient treatment of metabolic conditions such as diabetes and elevated cholesterol, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

28 Feb 2011

Preclinical data of Zalicus sodium channel compound published in journal PAIN

Zalicus Inc. today announced the publication of preclinical data in the journal PAIN. The paper describes the activity of Z212, a novel proprietary small organic compound that acts to modulate Nav1.7 and Nav1.8 sodium channels and to reduce neuropathic pain by targeting the hyper-excitability associated with chronic pain signaling pathways.

25 Feb 2011

Special issue of Neuron journal provides new insight into recent advances in addiction research

Addiction is a brain disease that destroys lives, devastates families and tears at the very fabric of society. Effective prevention and treatment of addiction requires a clear understanding of the complex brain mechanisms that underlie addictive behaviors, and research has provided a fascinating view of how substance abuse hijacks neuronal circuits involved in reward and motivation and causes profound and persistent changes in behavior.

24 Feb 2011

EpiCept 2010 fourth quarter net loss is $0.06 per share

EpiCept Corporation today announced operating and financial results for the fourth quarter and full year ended December 31, 2010, and provided an update on its key business initiatives.

24 Feb 2011

BDSI announces over 50% enrolled in BEMA Buprenorphine Phase 3 study in chronic pain

BioDelivery Sciences International, Inc. announced today that enrollment of its Phase 3 trial assessing the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain is on schedule, with over half of the needed subjects enrolled.

18 Feb 2011

Research: 75% of nonmilitary group medically evacuated for nonbattle injuries did not return to field

After analyzing data on 2,155 private contractors, diplomats and other civilians supporting war efforts in Iraq and Afghanistan who were medically evacuated out of combat zones, researchers have found they are more likely to be evacuated for noncombat-related injuries, but more likely to return to work in-country after treatment for these conditions.

15 Feb 2011

Zogenix completes enrollment in ZX002 Phase 3 study in opioid-experienced adults with moderate to severe pain

Zogenix, Inc. announced today the completion of enrollment in its pivotal Phase 3 efficacy study (Study 801) of ZX002. ZX002 is a novel, oral, single-entity, controlled-release formulation of hydrocodone for the treatment of moderate to severe pain in patients requiring around-the-clock opioid therapy for an extended period of time.

10 Feb 2011

Mallinckrodt receives FDA approval for Fentanyl Transdermal System patch ANDA

Covidien, a leading global provider of healthcare products, today announced that Mallinckrodt Inc., a Covidien company, has received U.S. Food and Drug Administration (FDA) approval of its Abbreviated New Drug Application (ANDA) for its Fentanyl Transdermal System (FTS) patch. Covidien is the largest supplier of controlled pain medications in the United States based on number of prescriptions.

10 Feb 2011

Positive results from EpiCept NP-1 Phase IIb trial in patients with CPN

EpiCept Corporation today announced positive results from a Phase IIb trial evaluating the efficacy and safety of EpiCept NP-1 in chemotherapy-induced peripheral neuropathy. EpiCept NP-1 is a topical analgesic cream containing two FDA-approved drugs, amitriptyline and ketamine, in development for the relief of pain from various peripheral neuropathies.

7 Feb 2011

Study: Fluorescent probe may serve as useful tool in future surgeries to repair injured nerves

Accidental damage to thin or buried nerves during surgery can have severe consequences, from chronic pain to permanent paralysis. Scientists at the University of California, San Diego School of Medicine may have found a remedy: injectable fluorescent peptides that cause hard-to-see peripheral nerves to glow, alerting surgeons to their location even before the nerves are encountered.

6 Feb 2011

Ameritox makes significant strides to advance its industry leadership position

Ameritox, the nation's leader in pain medication monitoring, made significant strides to advance its industry leadership position by strengthening the company's commitment to physicians and patients in the past twelve months.

5 Feb 2011